Patients receiving GDNF showed a 30–60% improvement in the off-medication motor sub-score of the Unified Parkinson’s Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub-score. This evidence concerns the gene GDNF and Parkinson disease.